{
    "Trade/Device Name(s)": [
        "ProNephro AKI\u2122 (NGAL)"
    ],
    "Submitter Information": "BioPorto Diagnostics Inc.",
    "510(k) Number": "K232761",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN130031"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PIG"
    ],
    "Summary Letter Date": "December 7, 2023",
    "Summary Letter Received Date": "September 8, 2023",
    "Submission Date": "September 8, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1220"
    ],
    "Regulation Name(s)": [
        "Acute Kidney Injury Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Neutrophil gelatinase-associated lipocalin (NGAL)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche cobas c 501 clinical chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced turbidimetric immunoassay"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for ProNephro AKI (NGAL) quantitative urine immunoassay for pediatric AKI risk assessment using Roche cobas c 501 analyzer",
    "Indications for Use Summary": "Quantitative immunoassay for NGAL in urine to aid in identifying pediatric ICU patients (\u22653 months to <22 years, no underlying kidney disease) at risk for moderate/severe AKI or persistent AKI, used within 24 hours of ICU admission, on Roche cobas c 501 analyzer",
    "fda_folder": "Clinical Chemistry"
}